Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Misses on EPS, Stock Down 24.47%

Aurinia Pharmaceuticals reported a loss of $0.19 per share, which was slightly worse than expected. The stock reacted negatively, dropping 24.47%, likely due to investor disappointment over the earnings results and the lack of revenue information. Without any guidance or management commentary, uncertainty remains about the company's future performance.